+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Shield Therapeutics Plc - logo

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of high unmet medical need. The company’s key products are Feraccru and PT20, one commercially available and one late-stage pharmaceutical for the treatment of iron deficiency anaemia and systemic phosphate accumulation. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

From
From
From
Intravenous Iron Drug Market 2020-2026 - Product Thumbnail Image

Intravenous Iron Drug Market 2020-2026

  • Report
  • September 2020
From
From
From
From
From
Hyperphosphatemia - Pipeline Review, H1 2020 - Product Thumbnail Image

Hyperphosphatemia - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 80 pages
From
Iron Drugs - Global Market Trajectory & Analytics - Product Thumbnail Image

Iron Drugs - Global Market Trajectory & Analytics

  • Report
  • April 2021
  • 184 pages
From
From
Drug Overview: Feraccru - Product Thumbnail Image

Drug Overview: Feraccru

  • Drug Pipelines
  • January 2018
  • 15 pages
From
Iron Deficiency Anemia - Pipeline Review, H2 2020 - Product Thumbnail Image

Iron Deficiency Anemia - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 96 pages
From
Iron Deficiency Anemia - Pipeline Insight, 2020 - Product Thumbnail Image

Iron Deficiency Anemia - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 pages
From
From
From
Loading Indicator
adroll